First Recreational Cannabis Dispensary Opens on Long Island

Industry stakeholders responded to the bill, which would prohibit the sale and possession of hemp-derived THC, among other restrictions.

In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.

Researchers analyzed data from 262 counties, identifying sociodemographic characterizations, associations, and discrepancies.

In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.

The report includes data from enrolled patients on products purchased, benefits, and side effects.

FDA Commissioner, Dr. Marty Makary, under the Trump Administration, announced in a recent interview that the government agency is making psychedelics a top priority.